Every 10-Q that Immunovant, Inc. (IMVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMVT filings page.
Immunovant, Inc., a clinical-stage immunology company focused on anti-FcRn antibody IMVT-1402, reported a net loss of $153.2 million for the quarter ended June 30, 2026, compared with $120.6 million a year earlier. Research and development expenses rose by $41.4 million to $142.6 million, driven by expanded IMVT-1402 programs in endocrine, neurological, rheumatology and dermatology diseases, while general and administrative expenses declined by $8.3 million to $17.7 million.
Cash and cash equivalents were $797.8 million, with operating activities using $124.4 million in cash in the quarter. Based on its current operating plan, the company expects this cash to fund operating expenses and capital expenditures to the potential commercial launch of IMVT-1402 in Graves’ disease, though it acknowledges a need to raise additional capital to fully implement its broader business plan.
The development pipeline centers on IMVT-1402 in six autoimmune indications, including potentially registrational trials in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof-of-concept study in cutaneous lupus erythematosus. In a difficult-to-treat rheumatoid arthritis trial, open-label Period 1 Week 16 results showed ACR20/50/70 response rates of 72.7%/54.5%/35.8% in a heavily pretreated population, with no new drug-related safety signals observed, and further data are expected in the second half of calendar 2026.
Immunovant, Inc. reported another quarter of heavy investment in its autoimmune pipeline, led by FcRn inhibitor IMVT-1402, with no product revenue yet. For the three months ended December 31, 2025, net loss was $110.6 million, similar to the prior year.
Quarterly research and development expenses were $98.9 million, reflecting multiple potentially registrational trials across Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof‑of‑concept study in cutaneous lupus. General and administrative expenses fell to $15.4 million as corporate spending moderated.
The company strengthened its balance sheet with a December 2025 underwritten equity offering of 26.2 million shares at $21.00, generating net proceeds of $543.6 million. Cash and cash equivalents rose to $994.5 million as of December 31, 2025, which management believes can fund announced indications through a potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant (IMVT) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $126.5 million for the quarter and $247.1 million for the six-month period, reflecting increased investment in clinical programs. Loss per share was $0.73 for the quarter and $1.43 year-to-date.
Research and development expenses rose to $114.2 million in the quarter (from $97.3 million), driven by potentially registrational trials across endocrine (Graves’ disease), neurology (myasthenia gravis, CIDP), rheumatology (difficult-to-treat RA, Sjögren’s), and a proof-of-concept in dermatology (cutaneous lupus). General and administrative expenses declined to $17.5 million from $18.5 million.
Cash and cash equivalents were $521.9 million, with operating cash outflows of $219.9 million for the six months. Management states this balance is expected to fund announced indications through the Graves’ disease readout in 2027. Shares outstanding were 174,532,710 as of September 30, 2025. The company has an unused at-the-market program of up to $150.0 million and a remaining $39.1 million minimum obligation for batoclimab manufacturing.
Immunovant is a clinical-stage immunology company advancing two anti-FcRn antibodies, IMVT-1402 and batoclimab. For the quarter ended June 30, 2025 the company reported a net loss of $120.6 million versus $87.2 million a year earlier, driven by higher research and development ($101.2 million versus $75.5 million) and increased general and administrative expense ($26.0 million versus $18.8 million). Cash and cash equivalents totaled $598.9 million at quarter end, down from $714.0 million three months earlier, and cash used in operations was $117.4 million.
The company has initiated multiple potentially registrational IMVT-1402 trials across Graves disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sj f6grens disease and a CLE proof-of-concept study, and expects a Graves disease readout in 2027. Batoclimab Phase 3 top-line results in thyroid eye disease are expected in the second half of 2025. Contractual commitments include an estimated $43.1 million remaining minimum purchase obligation to Samsung and potential milestone payments under the HanAll license up to $420.0 million (after $32.5 million previously paid).